M

Mersana Therapeutics
D

MRSN

0.31100
USD
-0.03
(-8.34%)
Market Closed
Volume
74,534
EPS
-2
Div Yield
-
P/E
-1
Market Cap
38,760,346
Related Instruments
AMGN
AMGN
4.42
(1.45%)
310.04 USD
C
CRSP
-1.550
(-4.53%)
32.650 USD
E
EDIT
-0.07000
(-5.88%)
1.12000 USD
INCY
INCY
0.180
(0.29%)
62.500 USD
N
NKTR
-0.05850
(-8.83%)
0.60430 USD
REGN
REGN
-14.36
(-2.30%)
610.88 USD
More
News

Title: Mersana Therapeutics

Sector: Healthcare
Industry: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.